Image

Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing

Acute Infectious Encephalitis and Myelitis in Guadeloupe by New Generation Sequencing

Recruiting
28 years and older
All
Phase N/A

Powered by AI

Overview

: Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. Next-generation sequencing could be used to correct an etiological diagnosis of these severe conditions in Guadeloupe. The rate of cases for which the infectious agent is not identified encourages continued diagnostic efforts, with the objective of identifying new pathogens or emerging pathogens, some of which may be more specific in the tropics.

Description

Encephalitis or myelitis is defined as the inflammatory or infectious involvement of the cerebral parenchyma or spinal cord. When an infectious origin is suspected, the germ is not always identified. In Guadeloupe, a region exposed to arboviruses, these infectious agents are among the causes of acute infectious attacks of the central nervous system. Other bacteria, parasites, or poorly known fungal agents may be responsible for these conditions. An observational study, retrospective over a period of 4 years, carried out at University Hospital of Guadeloupe, on cases of acute infectious attacks of the central nervous system, showed that the pathogen was not found in 45% of cases. Next Generation Sequencing (NGS) allows DNA or RNA sequencing faster and more accurately than other routine methods (serology / PCR). This technique could be used to correct an etiological diagnosis concerning these severe conditions in Guadeloupe, as part of a prospective study. Indeed, we find in the literature, more and more examples of patients suffering from these conditions of origin called "indeterminate", for which an etiological diagnosis is made thanks to the NGS, and sometimes a suitable curative treatment undertaken in the course of. A study of this type would be necessary to obtain exhaustive epidemiological data and to improve understanding of these severe pathologies, the consequences of which, in the short and long term, represent real public health issues. The main objective of the study is to describe, prospectively, the etiologies of acute encephalitis and myelitis at the University Hospital of Guadeloupe by carrying out diagnostic methods which may include NGS in patients without etiological diagnosis after having benefited from a first-line assessment. The secondary objectives are to describe the clinical, paraclinical and epidemiological characteristics of these conditions, and to describe long term outcomes

Eligibility

Inclusion Criteria:

  • We selected the following eligibility criteria for patients with acute encephalitis:
    • Patient of at least 28 days of life
    • With acute onset of symptoms for more than 24 hours
    • A major criterion among the following:
  • a disorder of consciousness or alertness
  • memory disorder
  • lethargy
  • modification of personal or behavioral disorder, irritability
  • confusion, disorientation in time or space

    \- At least two of the following minor criteria:

  • temperature above 38 ° C
  • new onset focal neurological deficit
  • epileptic crisis
  • biological abnormality of CSF (≥ 5 Leukocytes / mm3, protein ≥ 0.40 g / L)
  • partial or general epileptic seizure (s) not attributable to pre-existing epileptic disease and / or a recent focal neurological symptom
  • brain imaging suggestive of encephalitis, with EEG abnormalities suggestive of encephalitis
    • And absence of alternative diagnosis (intoxication, metabolic encephalopathy)
    • Persons affiliated or benefiting from a social security scheme;
    • Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research);
  • Eligibility criteria for Acute Transverse Myelitis Patients:
    • Patient of at least 28 days of life
    • Acute onset of symptoms for more than 24 hours
    • Medullary focal abnormality, responsible for motor, sensory or autonomic symptoms
    • contrast enhancement on bone marrow MRI and / or abnormal CSF (≥ 5GB / mm3, protein uptake ≥ 0.40 g / L)
    • Evolution between nadir and maximum symptoms, less than 4 weeks
    • Persons affiliated or benefiting from a social security scheme;
    • Having given free, informed, written and signed consent by the patient or his legal representative (no later than the day of inclusion and prior to any review required by the research);

Exclusion Criteria:

  • Primary vasculitis of the central nervous system or a documented specific impairment in an autoimmune condition
  • Cerebral thrombophlebitis if not associated with encephalitis
  • Meningitis without clinical or paraclinical argument for cerebral parenchymal involvement
  • Pyogenic abscess
  • Cerebral or spinal abscess
  • Tumoral or hematological pathology of the central nervous system
  • Toxic or metabolic encephalopathy
  • Transverse myelitis with vascular or traumatic origin
  • Known chronic infection with HTLV virus

Study details
    Acute Encephalitis
    Acute Myelitis

NCT07251049

Centre Hospitalier Universitaire de la Guadeloupe

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.